POP Biotechnologies' SNAP vaccine platform enters large-scale phase III clinical trials for COVID-19

Newswire and other websites report that UB spinoff POP Biotechnologies announced the start of two phase 3 clinical studies of EuCorVac-19, a COVID-19 vaccine candidate the startup is developing with South Korean partner EuBiologics.

The technology behind the vaccine comes from the lab of UB faculty member Jonathan Lovell, a POP Biotechnologies co-founder and SUNY Empire Innovation Associate Professor of biomedical engineering.

Read the story here.